Last updated: 2026-09-16 10:31:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
PRF Technologies Ltd. (PRFX) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $0.89, with a market capitalisation of $3.01M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.85 to $7.95. This page covers its latest market performance, valuation, price trends and company information.
$3.01M | |
$0.90 | |
$9,420.00 | |
$0.85 | |
$0.90 | |
2.13K | |
533.27K | |
-- | |
$7.95 | |
$0.85 | |
-- | |
-- |
PRF Technologies Ltd. (PRFX) is trading at $0.89 in pre-market trading as of 2026-09-16 10:22:00, down 1.33% ($0.01) from the previous close of $0.90
Pre-market trading shows how investors are pricing PRFX before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, PRF Technologies Ltd. (PRFX) moved from $0.97 to $0.89, representing a decline of 8.26% ($0.08).
The stock traded between $0.85 and $1.00 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 51.16 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 0.5%
PRFX is currently trading at $0.89, placing it 0.5% of the way from its 52-week low of $0.85 to its 52-week high of $7.95. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
PRF Technologies Ltd is a a diversified platform spanning speciality pharmaceuticals, drug-delivery technologies, and AI-driven renewable-energy analytics. PRF Technologies focuses on pharmaceutical therapies that emphasize reformulation and sustained-release drug-delivery technologies and AI-driven energy analytics. PRF-110, the company's lead product, is based on the local anesthetic ropivacaine and targets the postoperative pain relief market. The company has two operating segments composed of the Clinical Development segment, which facilitates the development of potential new drug compounds, and the Solar segment, which comprises the design and development of the company's intellectual property and the sale related service offerings.
| Employees | 6 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of PRF Technologies Ltd. (PRFX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.